Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00241384 · ClinicalTrials.gov registry record · Phase 3

Low Dose Supplemental External Radiation With Pd-103 Versus Pd-103 Alone for Prostate Cancer

A Phase 3 study of Prostate Cancer, sponsored by Schiffler Cancer Center.

Completed
Registry status
Phase 3
Development phase
396
Enrollment target
2
Study locations

NCT00241384: Completed Phase 3 study of Prostate Cancer, sponsored by Schiffler Cancer Center.

NCT00241384 is a Phase 3 study of Prostate Cancer that has completed, run by Schiffler Cancer Center. The registered enrollment target is 396 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (35% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT00241384, a Phase 3 study of Prostate Cancer, has completed, sponsored by Schiffler Cancer Center.

COMPLETED
Registry status
Phase 3
Development phase
396 participants
Enrollment target
2
Study locations

Study Summary

The primary purpose of this study is to evaluate two treatment regimens for prostate cancer, prostate implant with 20 Gy of external beam radiation therapy versus prostate implant with 0 Gy of external beam radiation therapy. Patients diagnosed with intermediate risk prostate cancer between the ages of 40 and 80 who have chosen brachytherapy with or without external beam radiation therapy as their intended treatment will be eligible and will be offered participation.

Primary Outcome

Serial PSA : 6, 12, 18 and 24 months and then yearly.

Conditions Studied

Interventions

  • PROCEDURE External beam radiation
  • PROCEDURE Pd-103

Study Locations (2)

Washington

  • Veterans Administration Puget Sound Health Care System - Seattle

West Virginia

  • Schiffler Cancer Center - Wheeling

Trial Details

FieldValue
Enrollment Target 396 participants
Start Date 2005-01
Est. Completion 2015-11
Phase Phase 3
Schiffler Cancer Center

3 total trials

What the finished NCT00241384 record still lists

NCT00241384 is an interventional study that assigns participants to a tested intervention. The registered 396 participants enrollment target is mid-sized for trials with a published cap, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (35% lower).

The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which External beam radiation is the first listed.

NCT00241384 reports a single indexed study location in Washington, West Virginia.

Frequently Asked Questions

What is clinical trial NCT00241384 about?

NCT00241384 is a clinical study titled "Low Dose Supplemental External Radiation With Pd-103 Versus Pd-103 Alone for Prostate Cancer". The primary purpose of this study is to evaluate two treatment regimens for prostate cancer, prostate implant with 20 Gy of external beam radiation therapy versus prostate implant with 0 Gy of external beam radiation therapy. Patients diagnosed with intermediate risk prostate cancer between the ages...

What is the current status of trial NCT00241384?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 396 participants. The study started on 2005-01. Estimated completion is 2015-11.

What conditions does trial NCT00241384 study?

This clinical trial studies the following conditions: Prostate Cancer.

What interventions are being tested in trial NCT00241384?

The interventions under investigation include: External beam radiation (PROCEDURE), Pd-103 (PROCEDURE).

Who is sponsoring clinical trial NCT00241384?

This trial is sponsored by Schiffler Cancer Center, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00241384 being conducted?

This trial has 2 study locations across Washington, West Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00241384's enrollment target sits among peer trials

396 133rd of 735 higher than 603 of 735 other Prostate Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05633615 · 396 participants · Phase 2

    Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

  • NCT06227910 · 396 participants · Phase 3

    A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease

  • NCT06545331 · 396 participants · Phase 1

    Study of XB010 in Subjects With Solid Tumors

  • NCT06666790 · 396 participants · NA

    DermaSensor Postmarket Surveillance Study

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00241384, the US trial registry maintained by the National Library of Medicine. NCT00241384 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.